Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.
about
Regulation of adaptive immunity; the role of interleukin-10Glatiramer acetate for multiple sclerosisT cell recognition of weak ligands: roles of signaling, receptor number, and affinitySynergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injuryWhere is biological therapy going?Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitusInfiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in miceAbsence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitisProfiling of alopecia areata autoantigens based on protein microarray technology.Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Biased T-cell antigen receptor repertoire in Lyme arthritis.The role of TNFalpha and lymphotoxin in demyelinating disease.Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity.Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.The application of gene therapy in autoimmune diseases.IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytesThe nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routesNasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: implications for clinical medicine.Developing antigen-specific therapies in multiple sclerosis: a tale of Tantalus or Ulysses?Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby.IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis.Degeneracy, as opposed to specificity, in immunotherapy.Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.Proteomics technologies for the study of autoimmune disease.Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading.A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11Role reversal: infiltrating T cells protect the brain.Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine.Immune regulatory mechanisms influence early pathology in spinal cord injury and in spontaneous autoimmune encephalomyelitis.T cell dynamics during induction of tolerance and suppression of experimental allergic encephalomyelitis.T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Investigation of the putative immunodominant T cell epitopes in coeliac disease.Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity.Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis.
P2860
Q21131215-C3A2ED48-C0DF-4685-A168-99D881FE7E90Q24235498-3A83FA48-EAF0-4764-9B37-C3CB9EDFF9C8Q24626152-37FFC62D-ED5F-4750-8F3D-839E71742485Q24678231-226550D3-17AF-4357-8035-A37001AD9057Q24792345-7887FD48-8D70-4475-B3A1-581D1A5665A6Q24792991-E13B39EF-A71F-4B15-8AFC-412EEE1B730BQ27307172-89769145-A0C2-4274-8F68-BB722BCFC44AQ28755978-743A647F-6A09-4835-83F8-2DFB7B9F3D7BQ30785189-7B2DFDD3-9C3E-49A2-961B-25CAA2D286E6Q33713319-FC292C59-207D-4CC5-8FC0-51315051C0D6Q33723154-2780984C-D623-4BF3-9535-0A121050B740Q33751598-46DFFB91-074D-4617-8FA7-BB43BE0AED2EQ33782397-E861EE4D-F3C3-4151-9900-0522FA0B1EE7Q33791198-3711F4CB-C348-44DC-8F3E-D943F0300201Q33801059-E15AAC1E-06F0-43FB-B9A4-F508C9D403E6Q33819182-1F03EDFC-537B-4F77-B0E4-8D7E973689E2Q33838467-BB54048F-ACBB-4FFA-9075-D01680FF65A8Q33840979-94A025CF-EAB8-4D3A-8225-83F7D9849A92Q33920273-BAA96BCC-4132-49AF-9EAD-14D3CD055B5FQ33947964-03CF30CD-1FCC-47B3-8C7A-9E5D5A22FCE8Q34106906-7B554C4F-2CC5-4D2C-8E0F-81BFB8AB0541Q34119484-A0F4251E-F845-45DC-932C-85BE52E20819Q34307160-D6160755-CCBE-4BE9-8D4F-614EF6ADDFC6Q34380578-60E66367-D515-43B8-97C1-16ED57FE8233Q34507783-DDDDDCE6-EA6C-40AF-BEA2-3611158B09F1Q34551385-968FE811-065A-4DD0-A7F0-E3162C0AA213Q34567730-7C872152-9264-4FD4-9770-23199B82297CQ34601748-60E4E368-EBC4-4951-BEF6-782C93626169Q34792611-E09D22B8-7439-4B08-9D0F-B3AEDD2F55C8Q34795755-1C28F6E2-D8F1-451C-B525-0AC6A124FF98Q34798966-FE1D605B-31C2-4251-AE04-C65B13638A3DQ35056732-C3B8C839-9F09-483D-8F8A-1D151CD1D885Q35081451-B77E4AC3-AB6A-4A4A-86D8-409D7B9D534BQ35083879-79088984-859B-415F-AE29-5242A6E0C593Q35269080-C138287F-6AC0-4892-A57E-3BEF10AF9F67Q35558638-ADF3861C-EF90-4219-8318-A835847F9D85Q35589934-ABB60A5C-F09A-4A27-A6D6-2B84BCC856BFQ35598350-787E3D8F-EB75-4847-8A1F-6DFFA48F9CC7Q35675262-D1FBE4CD-D0CF-43C6-AB7A-927B5287EE1AQ35764734-8991B56E-1CD1-4A0F-9C76-FB7307563BF3
P2860
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Treatment of experimental ence ...... logue of myelin basic protein.
@en
Treatment of experimental ence ...... logue of myelin basic protein.
@nl
type
label
Treatment of experimental ence ...... logue of myelin basic protein.
@en
Treatment of experimental ence ...... logue of myelin basic protein.
@nl
prefLabel
Treatment of experimental ence ...... logue of myelin basic protein.
@en
Treatment of experimental ence ...... logue of myelin basic protein.
@nl
P2093
P356
P1433
P1476
Treatment of experimental ence ...... logue of myelin basic protein.
@en
P2093
Allegretta M
Blankenstein T
Fairchild PJ
Fathman CG
P2507
P2888
P304
P356
10.1038/379343A0
P407
P50
P577
1996-01-01T00:00:00Z
P6179
1053615623